Shen Hsin-Wei, Vice President of Medical Affairs, BizLink Biotech Venture Capital

The development of medical devices is a high-risk, long-cycle journey under intensive regulatory oversight. From the initial concept to market launch, every innovative product must pass through multiple critical gates, including clinical validation, regulatory review, manufacturing scale-up, and market adoption.

Successful medical product development relies on precise management of each milestone and the strategic planning that connects them. In today’s aging societies and the growing prevalence of chronic diseases, demand for efficient, safe, and affordable medical devices continues to rise. Being able to navigate the development process in a systematic way has become a fundamental competency for both startups and established medical companies.

1. Identifying Clear Clinical Needs: From Insight to Concept

In the early phase of product development, the most important task is to confirm whether there is a clear clinical need. This is usually accomplished through conversations with frontline clinicians, direct observation of care settings, and literature review, to clarify what is often referred to as “Unmet Needs.”

Many innovations exhibit technical brilliance but lack support from real clinical pain points, and as a result, fail to enter the market. At this stage, conducting in-depth interviews with frontline medical staff and observing problems that are “overlooked yet repeatedly occurring” in clinical workflows can help verify the authenticity and urgency of the need.

Once the need is confirmed, the development team can propose an initial solution concept and perform market and competitive landscape analysis, establishing a logical linkage between the problem and the proposed solution. The outcome of this phase not only defines the direction of subsequent product design but also helps in securing early-stage funding and strategic partnerships.

2. Technical Feasibility: Can It Be Built and Scaled?

Once the concept is clearly defined, the process moves into the technical feasibility assessment phase. The core question here is whether the product is technically achievable, including:

• Selection of materials

• Development of early prototypes

• Testing of basic functions and performance

At the same time, engineering and supply chain teams must evaluate manufacturing cost and scalability. A common mistake at this stage is to overlook the risks and challenges associated with future scale-up, leading to difficulties in mass production or unsustainable costs.

Technical feasibility is not just about whether something can be built; it is about whether the solution can balance quality, cost, and time in a way that supports eventual commercialization. If the team can build an initial prototype and obtain preliminary validation through bench tests or simulations, it will provide solid support for subsequent clinical and regulatory phases.

3. Regulatory Strategy: Choosing the Right Path Early

As the technology begins to take shape, regulatory strategy becomes a key milestone.

Each country has its own classification system and approval pathways for medical devices. Based on the intended use and risk level of the product, the team must determine the appropriate classification (such as Class I, II, or III) and corresponding review pathway. Different classes are associated with different review mechanisms and clinical evidence requirements—some products may qualify for simplified pathways (e.g., U.S. 510(k)), while others must undergo full clinical evaluation and PMA review.

Teams must carefully evaluate:

• Regulatory trends in target markets

• Review priorities of agencies (e.g., FDA, TFDA, EU MDR)

• Special requirements for categories such as software or AI-based devices

By clarifying the regulatory strategy early, teams can systematically plan the necessary tests, allocate resources, and develop realistic timelines. The quality of preparation at this stage often determines whether a product can enter the market on schedule and obtain the required approvals.

4. Design Verification and Risk Management: Building a Safe System

Once the regulatory pathway is defined, design verification and risk management come into focus.

The development team must verify that the device meets previously defined Design Inputs and Design Outputs, and complete a variety of design tests, including:

• Mechanical and structural testing

• Electrical and functional performance testing

• Biocompatibility and safety evaluations

Risk analysis tools such as FMEA are critical at this stage to anticipate potential failure modes in real-world use and to reduce associated risks.

This phase tests not only technical execution capability but also the team’s systems thinking—how to ensure safety and regulatory compliance without sacrificing innovation and clinical applicability. The completeness of design verification will be a central criterion for regulatory authorities during review and must not be treated lightly.

5. Clinical Validation: Proving Safety and Effectiveness in Practice

Clinical validation further confirms the safety and effectiveness of the device in actual use.

Depending on the risk classification, the product may require only a simple observational study, or it may need a full formal clinical trial. Clinical study protocols must be submitted for approval to:

• Institutional Review Boards (IRB)

• Competent regulatory authorities

and executed in compliance with GCP (Good Clinical Practice).

Upon completion, if the data support the safety and effectiveness of the device, the results can be incorporated into the regulatory submission dossier. Challenges at this stage are not only scientific, but also practical:

• Securing collaboration from medical institutions

• Recruiting appropriate patients

• Managing trial costs and execution risks

Establishing strategic partnerships with key clinical sites can greatly enhance the efficiency and credibility of clinical validation.

6. Regulatory Submission and Approval: From Dossier to Clearance

Before market launch, the team must submit a complete registration dossier to the relevant regulatory authority, including:

• Technical documentation

• Design and development history

• Test reports and validation data

• Clinical evidence

• Risk management files

• Quality system descriptions

This is the stage where the team formally engages with reviewers, responding to questions and providing supplemental information in a timely manner to secure approval.

Review culture and procedures differ across regions. For example:

• The FDA encourages early interaction through Pre-submission Meetings for innovative technologies.

• The EU places strong emphasis on the completeness of technical documentation and the consistency of clinical evidence under MDR.

This process can take anywhere from several months to over a year. Therefore, early preparation and flexibility in response are essential.

7. Manufacturing Scale-Up: From Prototype to Stable Production

Once approvals are obtained, the product must be transitioned into stable mass production. This includes:

• Factory capacity ramp-up

• Optimization of production processes

• Establishment and implementation of quality management systems (e.g., ISO 13485)

• Process validation

Manufacturing must ensure batch-to-batch consistency, as well as robust systems for:

• Incoming inspection

• In-process quality control

• Final inspection and field feedback

Supply chain risk management is also crucial—such as identifying alternative sources for critical components and preparing contingency plans.

For startups, this phase represents the critical transition from laboratory-scale innovation to industrial-scale execution.

8. Market Introduction and Early Commercialization

After entering the market, the product moves into the market introduction and early commercialization phase.

Key activities include:

• Collaboration with Key Opinion Leaders (KOLs)

• Training programs for hospitals and clinical staff

• Marketing, education, and product promotion

If the product is intended to be reimbursed, additional tasks include:

• Health insurance or reimbursement applications

• Pricing and coding strategy

Market feedback—such as user satisfaction, adverse event reports, training outcomes—must be collected systematically and fed back into product development and business processes.

Successful market introduction is not only measured by short-term sales, but also by the speed at which brand trust and usage habits are established. This is essential for the long-term survival and growth of any medical device.

9. Post-Market Surveillance and Product Upgrades

In the final stage, the focus shifts to post-market monitoring and continuous improvement.

Based on real-world feedback, the team may:

• Optimize existing product features

• Fix issues discovered in the field

• Develop new versions or expanded product lines

These improvements may include:

• Design refinements and usability enhancements

• Additional functionality

• Digital or AI-based upgrades

If changes involve core design or intended use, new regulatory submissions may be required, so this stage must be approached carefully.

Through continuous monitoring and close user engagement, teams can:

• Identify new market opportunities

• Reduce the risk of recalls and legal issues

• Sustain product value throughout its lifecycle

Conclusion: Milestones as the Rhythm of Medical Innovation

Medical device development is a marathon, not a sprint. Milestones are not just items on a checklist; they shape the rhythm, confidence, and discipline of the development and founding team.

By clearly defining the objectives, methods, and evaluation criteria at each stage—and combining this with deep understanding of regulations, manufacturing, and market dynamics—innovations can move beyond the lab, enter real clinical practice, and bring tangible change to patients and healthcare professionals.

The journey is long, but every milestone achieved is a critical step toward realizing the vision of medical innovation.